Value proposition

We provide drug developers with high-quality data to give them the confidence to take their drug discovery forward.

RoukenBio – CRO redefined.

RoukenBio takes its tagline seriously - disrupting the traditional CRO model with a collaborative, personalised approach to drug discovery. With customers in over 27 countries, RoukenBio aims to become the most trusted research partner to biotherapeutic innovators globally.

Backed by brilliant minds, RoukenBio offers a range of in vitro drug discovery services with specialist expertise across human immunology, bioanalytical, cell line engineering, molecular biology, bioassay development and safety and efficacy assessments.

RoukenBio partners with therapeutic developers from early discovery, through IND-enabling pivotal data studies, to ‘GMP-ready’ potency assay creation. Working across inflammation, auto-immunity, immuno-oncology and oncology, their team focuses on novel and emerging therapeutic classes including antibodies, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines, antibody drug conjugates and more. RoukenBio embraces change and drives innovation with unique services, like the customisable inducible cell line platform, IndEx-2, to stay ahead of the curve. RoukenBio’s assay solutions recreate disease state pathologies as faithfully as possible, and combined with a thought-partner approach to research collaborations, the RoukenBio team uses their scientific empathy to propel their customer’s therapeutic development projects forward.

Bioassays, ADCC, mAbs, ADCs, Bi-specifics, Biosimilars, Immuno-oncology, Method development, t cell activation, t cells, tumor microenvironment, TDCC, cell line development, checkpoint inhibitors, immunology, immunotherapeutics, antibodytherapeutics, immune cell engagers, CRO, services, biologics, NK cells, macrophages, dendritic cells, drug development, CAR-T, drug discovery, cell therapy, and Tregs